NCT07535359
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07535359
Title Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Recruitment Available
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Daiichi Sankyo
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Central Care Cancer Center AVAILABLE Salina Kansas 67401 United States Details
Duke Cancer Institute AVAILABLE Durham North Carolina 27710 United States Details
University of Texas Southwestern Medical AVAILABLE Dallas Texas 75390 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field